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The microsomal enzyme cytochrome P450c17 is an important
regulator of steroidogenesis. The enzyme has two functions:
17-hydroxylase and 17,20-lyase activities. These functions
determine the ability of adrenal glands and gonads to syn-
thesize 17-hydroxylated glucocorticoids (17-hydroxylase
activity) and/or sex steroids (17,20-lyase activity). Both en-
zyme functions depend on correct steroid binding, but it was
recently shown that isolated lyase deficiency can also be
caused by mutations located in the redox partner interaction
domain. In this article we present the clinical history and
molecular analysis of two patients with combined 17-hydrox-
ylase/17,20-lyase deficiency and four patients with isolated
17,20-lyase deficiency. In these six patients, four missense
CYP17 mutations were identified. Two mutations were lo-
cated in the steroid-binding domain (F114V and D116V), and
the other two mutations were found in the redox partner
interaction domain (R347C and R347H). We investigated the
activity of these mutated proteins by transfection experi-
ments in COS-1 cells using pregnenolone, progesterone, or
their hydroxylated products as a substrate and measuring
17-hydroxylase- and 17,20-lyase-dependent metabolites in
the medium. The mutations in the steroid-binding domain
(F114V and D116V) of P450c17 caused combined, complete
(F114V), or partial (D116V) 17-hydroxylase and 17,20-lyase
deficiencies, whereas mutations in the redox partner inter-
action domain (R347C and R347H) displayed less severe 17-
hydroxylase deficiency, but complete 17,20-lyase deficiency.
These findings are consistent with the clinical data and sup-
port the observation that the redox partner interaction do-
main is essential for normal 17,20-lyase function of P450c17.
(J Clin Endocrinol Metab 87: 5714–5721, 2002)
IN THE STEROIDOGENIC pathway, cholesterol is con-verted into pregnenolone, which subsequently can be
processed to either mineralocorticoids (no 17-hydroxyla-
tion) or glucocorticoids (17-hydroxylation) in adrenal
glands or to sex steroids in adrenals and gonads (17-
hydroxylation and 17,20-lyase activity). The microsomal en-
zyme cytochrome P450c17 is an important switchpoint in this
steroidogenic pathway because it has both 17-hydroxylase
and 17,20-lyase activities (Fig. 1). The first step necessary for
P450c17 enzyme activity is steroid binding; then electron
transfer occurs, enhanced by oxidoreductase to catalyze the
hydroxylase reaction. The lyase activity is dependent on
facilitation of the interaction of oxidoreductase with the re-
dox partner-binding site (1). This interaction is enhanced by
cytochrome b5 (2) or phosphorylation of phosphoserine res-
idues (3). Optimal functioning of the redox partner-binding
site is especially essential for the lyase reaction.
The P450c17 enzyme is encoded by the CYP17 gene, which
is located on chromosome 10q24.3 (4). CYP17 gene mutations
are known to cause either complete or partial, combined, or
isolated 17-hydroxylase/17,20-lyase enzyme deficiencies.
The study of these mutant enzymes found in patients with
17-hydroxylase/17,20-lyase enzyme deficiencies can help
us to understand the factors involved in P450c17 enzyme
function. Until now 15 single base pair CYP17 gene muta-
tions have been found, causing combined 17-hydroxylase
and 17,20-lyase deficiencies (Table 1) (5–19). Only 2 muta-
tions identified in patients with isolated complete 17,20-lyase
deficiency were examined in vitro (Table 1) (14). These 2
mutations (R347H and R358Q) are located in the redox part-
ner interaction domain. The observation of differential re-
sidual enzyme activity in naturally occurring mutations in
various regions of the CYP17 gene supports the hypothesis
that 17,20-lyase activity depends on normal function
of the redox partner interaction site of the P450c17 enzyme
(Fig. 1) (20).
In this article we present the clinical and molecular data of
six patients with 17,20-lyase deficiency. In the CYP17 gene of
these patients four different missense mutations were iden-
tified. Two mutations were located in the steroid-binding
domain and two in the redox partner interaction domain. The
effects of these four mutations on the enzymatic activity of
the protein were examined by in vitro expression studies.
Subjects and Methods
Patients
The clinical picture and hormone levels of patient 1 have been de-
scribed previously (21). This 17-yr-old female patient was referred be-
Abbreviations: AIS, Androgen insensitivity syndrome; DHEA, de-
hydroepiandrosterone; hCG, human chorionic gonadotropin; Vmax,
maximum velocity.
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cause of primary amenorrhea and lack of secondary sexual development
(Tanner stage M1P1). She had one sister with normal secondary sexual
development. The patient had female external genitalia, but no uterus
and a 46,XY karyotype. Based on these results, the presumptive diag-
nosis of androgen insensitivity syndrome (AIS) was made. Secondary
sexual development began after the start of estrogen substitution ther-
apy. The patient underwent a hormonal evaluation before undergoing
bilateral gonadectomy at the age of 20 yr. With the exception of fatigue,
she had no complaints. Her blood pressure was elevated (150/110 mm
Hg) despite low renin levels. Basal levels of androgens were low, and
progesterone levels were high; basal cortisol was within the normal
range, but rose insufficiently after ACTH (Table 2). These findings led
to the diagnosis of combined 17-hydroxylase/17,20-lyase deficiency.
Results of in vitro studies of testis tissue of this patient, using preg-
nenolone, 17-hydroxypregnenolone, and dehydroepiandrosterone
(DHEA) as substrate, followed by measurement of metabolites confirmed
the absence of 17-hydroxylase and 17,20-lyase activities (21).
Patient 2 is a 46,XY individual, who was born with an enlarged clitoris
and no uterus. Her gonads were removed when she was 3 yr old. Based
on the combination of ambiguous genitalia, lack of pubic hair at puberty,
low-normal levels of androgens, and cortisol (Table 2), combined partial
17-hydroxylase/17,20-lyase deficiency was diagnosed.
Patient 3 was born with complete female external genitalia and raised
as a girl. She was the first child of consanguineous parents. The family
history did not reveal any sexual differentiation disorders. At the age of
2 months, she had bilateral inguinal hernias, which contained testes, and
subsequently, her karyotype was shown to be 46,XY. The presumptive
diagnosis of AIS was made, and gonadectomy was performed. She was
reevaluated at the age of 10 yr. Her blood pressure was 140/80 mm Hg
despite normal renin levels. She underwent uneventful surgery twice.
Basal levels of androgens were low, and progesterone was elevated. An
ACTH test showed a low-normal basal level of cortisol that did not
respond to ACTH (Table 3), suggesting partial 17-hydroxylase defi-
ciency with complete 17,20-lyase deficiency.
Patient 4, raised as a girl, was evaluated at age 14 yr because of
delayed puberty. She had a 46,XY karyotype and complete female ex-
ternal genitalia with an absent uterus. The presumptive diagnosis of AIS
was made, and she underwent gonadectomy. At age 28 yr she was
TABLE 1. All single base pair missense mutations in the CYP17 gene described until now, their location, and their residual enzyme
activity studied in vitro
Mutation 17-Hydroxylase(%)
17,20-Lyase
(%) Site of mutation
a Reference
R35L 38 33 Membrane 15
Y64S 15 Membrane 8
G90N 1 1 11
F93C 11 10 Steroid 19
R96W 25 25 12
S106P 1 1 Steroid 5
F114V 2.2 1 Steroid This article
D116V 37.7 10.7 Steroid This article
N177D 10 10 Steroid 15
P342T 20 20 6
R347H 65 5% Redox 14
44.1 1 This article
R347C 13.6 1 Redox This article
R358Q 65 5 Redox 14
H373L 1 1 Heme 9
P409R 1 1 Steroid 16
R415C 8 10 Heme(?) 18
F417C 1 1 Heme 13 and 14
R440H 1 1 Heme 10
R496C 10 10 Heme 7
R496H 38 33 Heme 15
a Membrane, Membrane attachment domain; Steroid, steroid binding domain; Redox, redox partner interaction domain; Heme, heme binding
domain; and Heme(?), uncertainty of affected domain (28).
FIG. 1. Model of the mechanism of action of micro-
somal P450c17 and its differential regulation of 17-
hydroxylase and 17,20-lyase activities. OR, Oxi-
doreductase; b5, cytochrome b5; e, electron
transfer [adapted from Auchus et al. (2)].
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reevaluated. Her blood pressure was 170/90 mm Hg despite normal
renin levels. She underwent surgery several times without complica-
tions. She developed breasts on estrogen substitution. Her main com-
plaint was the complete absence of pubic hair, which developed with
testosterone propionate ointment therapy. Basal levels of androgens
were extremely low with elevated progesterone. She had low-normal
basal levels of cortisol, which did not rise after ACTH stimulation (Table
3). These data are consistent with partial 17-hydroxylase deficiency and
complete 17,20-lyase deficiency.
Patients 5 and 6 are siblings from consanguineous parents. Both 46,XY
siblings were born with ambiguous external genitalia (Prader stage III).
Patient 5 was assigned the male sex, and patient 6 was assigned the
female sex on the basis of the sex designated by the parents at birth.
There were no clinical signs of insufficient cortisol secretion. Both sib-
lings underwent surgery several times without complications. Their
basal serum levels of androgens were low and rose insufficiently after
human chorionic gonadotropin (hCG) stimulation. Basal plasma renin
activity was normal. Progesterone and 17-hydroxyprogesterone levels
were high after hCG stimulation, and basal serum levels of cortisol were
normal with some, but insufficient, rise during ACTH treatment (Table
4). On the basis of these observations the diagnosis of isolated 17,20-lyase
deficiency was made.
Mutation analysis of the CYP17 gene
Genomic DNA was isolated from leukocytes according to standard
procedures (22). Exons 1–8 and their flanking intron sequences of the
CYP17 gene were amplified individually by PCR using the primers and
PCR conditions described by Monno et al. (5), followed by single strand
conformation polymorphism analysis (23) and sequencing of the frag-
ments that showed abnormal single strand conformation polymorphism
patterns. To determine whether two mutations identified in the same
patient were on separate alleles, allele-specific amplification was carried
out (patient 3), or DNA of the parents was sequenced (patients 1, 2,
and 4).
Construction of mutant expression plasmids
Mutant CYP17 expression plasmids were constructed using the con-
ditions described previously for the LH receptor (24). pcDNA3 was used
as the expression vector. For the exchange of fragments containing the
mutation in the wild-type CYP17 expression vector, flanking primers
were used: T7 forward, AATACGACTCACTATAG; and 638 reverse,
CTGTATGACATTCAACTC for the F114V and D116V mutants; and 670
forward, GCAAAGACAGCCTGGTGGACC; and SP6 reverse, CTAT-
AGTGTCACCTAAAT for the R347C and R347H mutations. The frag-
ments were digested with the restriction enzymes BamHI and BstEII for
the F114V and D116V mutants and BspEI and XhoI for the R347C and
R347H mutations, respectively, and subsequently ligated into the ex-
pression vector that had been digested with the same enzymes. Primers
that carry the mutation were as follows: F114V, GGGTATCGC-
CGTCGCTGACTCTG; D116V, CGCCTTCGCTGTCTCCGGAGCA-
CACTGG; R347C, CAGTGACTGTAATCGATTGCTCCTGCTG; and
R347C, CCAACTATCAGTGATCATAACCGTCTC and their reverse
complements.
Culture and transfection of cells
COS-1 cells were grown in 24-well plates to 50% confluence and
transfected with 0.4 g/well (four wells per plasmid) of pcDNA ex-
pression plasmid containing wild-type or mutant CYP17. Transfection
efficiency was monitored by cotransfection with a -galactosidase ex-
pression plasmid. The transfected cells were washed and incubated in
fresh medium. After 40 h when the COS-1 cells were 80–90% confluent,
1 m pregnenolone, progesterone, 17-hydroxypregenenolone, or 17-
hydroxyprogesterone was added to the medium. After 8 h, i.e. during
the period of linear steroid production against time (data not shown), the
medium was removed and assayed for products using RIAs for 17-
hydroxypregnenolone (DRG Diagnostics, Marburg, Germany) and
DHEA or 17-hydroxyprogesterone and androstenedione (Diagnostic
Products, Los Angeles, CA). All transfections were performed at least
twice.
TABLE 2. Serum hormone concentrations of patients 1 and 2 with CYP17 mutations in the steroid binding domain
Hormone
Patient 1 (F114V)a Patient 2 (D116V)a
Basal ACTH Basal
LH (U/liter) 107.4 (1.5–9.4)
FSH (U/liter) 38.4 (2.6–7.4)
Progesterone (nmol/liter) 14.5 (0.5–2) 14.9 3.2 (0.5–2)
17OH-progesterone (nmol/liter) 0.29 (10) 0.31 0.1 (10)
Cortisol (nmol/liter) 220 (200–800) 240 (500) 248 (200–800)
DHEA (nmol/liter) 0.1 (3.5–25) 0.1 3.6 (3.5–25)
Androstenedione (nmol/liter) 0.1 (2–10) 0.1 1.67 (2–10)
Testosterone (nmol/liter) 0.2 (0.5–3) 0.2 0.3 (0.5–3)
Renin (pg/ml) 0.1 (0–2.5) 0.1
Normal age-adjusted reference values are shown in parentheses. In the ACTH test, venous catheters were inserted, and serum levels of several
hormones were determined in blood samples taken before and at 60 min after the iv administration of 0.25 mg ACTH.
a Age: patient 1, 17 yr; patient 2, 27 yr.
TABLE 3. Serum hormone concentrations of patients 3 and 4 with CYP17 mutation R347C in the redox partner interaction domain
Hormone
Patient 3 (R347C)a Patient 4 (R347C)a
Basal ACTH Basal ACTH
LH (U/liter) 6.4 (1) 5.4 10.6 (1.5–8)
FSH (U/liter) 41.5 (1) 46.5 37.3 (2–7)
Progesterone (nmol/liter) 7.4 (0.5–2.0) 8.4 6.1 (0.5–2) 12.2
17OH-progesterone (nmol/liter) 2.4 (0.4–2.1) 2.6 (3.5–6.0) 1.9 (10) 2.4
Cortisol (nmol/liter) 216 (200–800) 228 (500) 232 (200–800) 285 (500)
DHEA (nmol/liter) 0.3 (0.4–4.9) 0.5 (1.2–9.4) 0.0 (3.5–25) 0.0
Androstenedione (nmol/liter) 0.11 (0.24–0.8) 0.13 (0.4–1.6) 0.57 (2–10) 0.51
Testosterone (nmol/liter) 0.1 (1) 0.1 0.1 (0.5–3.0)
Renin (pg/ml) 12.5 (60–300) 10.2 (60–300)
Normal age-adjusted reference values are shown in parentheses. The ACTH test is described in the legend to Table 2.
a Age: patient 3, 10 yr; patient 4, 28 yr.
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In separate experiments, Km and maximum velocity (Vmax) were
measured for the 17-hydroxylase and 17,20-lyase activities of the en-
zyme by culturing the cells in the presence of 0.1, 0.2, 0.5, 1, or 2 m
pregnenolone or 17-hydroxypregnenolone, respectively, and measuring
the concentration of the above-mentioned products using the same
assays. Results were obtained with three or four wells of transfected cells
per dose and were corrected for the concentrations measured in the
medium of cells transfected with the empty vector.
Results
Mutations
The mutations identified in the CYP17 gene of our six
patients are shown in Table 5. Mutation analysis of patients
1, 2, and 4 revealed compound heterozygosity for three novel
mutations: F114V (TTC3GTC), D116V (GAC3GTC), and
R347C (CGT3TGT), combined with a frameshift mutation
on the other allele: a 4-base duplication near codon 480. This
duplication has previously been observed in several families
of Dutch and German Mennonite descent and is known to
completely abolish all P450c17 enzyme activity (25). The
novel mutations identified in patients 1 and 2 (F114V and
D116V) are in the steroid-binding domain. Patient 3 was a
compound heterozygote for two new mutations: R347C
(CGT3TGT) and a 25-bp deletion in exon 1 (nucleotides
204–228 of the coding sequence, counting from the A of the
start codon). This deletion renders the message out of frame,
resulting in a premature stop codon located at 28 residues
after the deletion. We therefore expect that this deletion in
allele 2 does not lead to the production of any functional
protein. Patient 4 showed the same R347C mutation in one
allele, whereas the 4-bp dup exon 8 mutation that was also
present in patients 1 and 2 was present in the other. The
mutation R347C is located in the redox partner interaction
domain. Localization of two different mutations identified in
the CYP17 gene in patients 1–4 on separate alleles was con-
firmed by determining that each of their parents carried only
one of these mutations (patients 1, 2, and 4) or by allele-
specific amplification (patient 3). Finally, patients 5 and 6
(siblings) were homozygous for the R347H (CGT3CAT)
mutation that has been described previously (14).
Expression of mutant proteins in COS-1 cells
The 17-hydroxylase and 17,20-lyase activities of the mu-
tated proteins were estimated using transient transfection in
COS-1 cells and compared with those of the wild-type en-
zyme. The conversion of various concentrations of preg-
nenolone to 17-hydroxypregnenolone and DHEA was used
as a measure for 17-hydroxylase activity. Results are shown
in Fig. 2A. Lineweaver-Burk plots calculated from these data
are shown in Fig. 3. The r values for the regression lines were
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TABLE 5. Mutations identified in the CYP17 gene of six patients
Patient Allele 1 Site of mutationa Allele 2
1 F114V Steroid 4-bp duplication exon 8
2 D116V Steroid 4-bp duplication exon 8
3 R347C Redox partner 25-bp deletion exon 1
4 R347C Redox partner 4-bp duplication exon 8
5 and 6 R347H Redox partner R347H
a Steroid indicates steroid binding domain; redox partner indicates
redox partner interaction domain (28).
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all above 0.95. Resulting apparent values for Km and Vmax
have been summarized in Table 6. All Vmax values for the
mutated proteins were lower than that for the wild-type
protein, whereas Km values of the proteins with mutations in
the steroid-binding domain were comparable to that of the
wild-type protein, and the Km values for the other two pro-
teins were lower. As an example for the separate amounts of
17-hydroxypregnenolone and DHEA produced, the data ob-
tained with 1 m pregnenolone are plotted in Fig. 4. The use of
a logarithmic axis allows a more clear indication of the amounts
of DHEA. The wild-type enzyme and the F114V and D116V
mutants converted between 10–20% of 17-hydroxypreg-
nenolone to DHEA, whereas the R347C and R347H mutants did
not produce measurable concentrations of DHEA despite the
production of 17-hydroxypregnenolone.
Similar results were obtained using 17-hydroxypreg-
nenolone as the substrate (Fig. 2B). Significant amounts of
DHEA were only produced by the wild-type enzyme and the
D116V mutant. The apparent Vmax and Km values for the
wild-type enzyme were 1.55 min1 and 0.35m, respectively.
The production of DHEA by the mutated enzymes was too
low to calculate Vmax and Km for the 17-hydroxypreg-
nenolone to DHEA conversion by these enzymes. Conver-
sion percentages at the highest concentration of 17-
hydroxypregnenolone (2 m) were 31.3%, 0.15%, 4.8%,
0.03%, and 0.12% for wild-type, F114V, D116V, R347C, and
R347H, respectively.
When progesterone was used as a substrate for testing the
4-steroid biosynthetic pathway, the production of 17-
hydroxyprogesterone, indicative of hydroxylase activity,
showed a similar pattern as the production of 17-
hydroxypregnenolone from pregnenolone, but at lower lev-
els (Fig. 5). With neither progesterone nor 17-hydroxypro-
gesterone (results not shown) as substrate did we observe
significant production of androstenedione by the mutant
FIG. 2. Production of 17-hydroxypregnenolone (17OH-Preg) and
DHEA after 8-h culture of transfected COS-1 cells in the presence of
various concentrations of steroid precursors as a measure of 17-
hydroxylase activity (A; culture with pregnenolone) and of 17,20-lyase
activity (B; culture with 17-hydroxypregnenolone). The cells were
transiently transfected with wild-type CYP17 and the CYP17 mu-
tants. Substrate concentrations were 0.1, 0.2, 0.5, 1, or 2 M. Data are
the mean  SEM (n  3 in A and n  4 in B).
FIG. 3. Lineweaver-Burk plot for the conversion of pregnenolone to
17-hydroxypregnenolone plus DHEA, shown in Fig. 2A, by wild-type
CYP17 (F), and the D116V (‚), R347C (E), and R347H (Œ) mutants.
Results for the F114V mutant are not shown, because all measured
values are outside the axes used.
TABLE 6. Enzyme kinetic data on the 17-hydroxylase activity of
the CYP17 mutants investigated
Wild type F114V D116V R347C R347H
Km (M) 0.97 0.76 0.95 0.08 0.27
Vmax (min1) 3.0 0.04 0.56 0.10 0.50
FIG. 4. Separate productions of 17-hydroxypregnenolone (f) and
DHEA () from 1 M pregnenolone by the COS-1 cells described in
Fig. 2A. Note the logarithmic y-axis.
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proteins, indicating the absence of 17,20-lyase activity under
these conditions.
Discussion
Combined 17-hydroxylase/17,20-lyase deficiency (pa-
tients 1 and 2) is a well defined disorder (26). Isolated 17,20-
lyase deficiency (patients 3–6) with subnormal 17-hydrox-
ylase function leading to a female phenotype or ambiguous
genitalia, absence of sexual development, and normal basal
cortisol levels without hypertension is extremely rare, with
few clinical data. Isolated 17,20-lyase deficiency can be dif-
ferentiated from combined 17-hydroxylase/17,20-lyase
deficiency by an ACTH test, showing elevated progesterone
in 17-hydroxylase-deficient patients and elevated 17-
hydroxyprogesterone with subnormal rise of cortisol in pa-
tients with isolated 17,20-lyase deficiency. All of our patients
had normal basal cortisol serum levels, but insufficient re-
sponse to stimulation by ACTH. No guidelines are available
for the hydrocortisone substitution treatment in these pa-
tients. In our view, daily hydrocortisone substitution treat-
ment is not needed when there are no complaints, but in case
of stress, a hydrocortisone stress dose is advised. Neverthe-
less, some of our patients underwent uneventful surgery
without a hydrocortisone stress scheme.
In four of our six patients (patients 1–4), one allele of the
CYP17 gene was completely inactive due to insertions or
deletions resulting in a frameshift. Patient 1 had a missense
mutation in the steroid-binding domain in the other allele:
F114V. This resulted in a combined complete 17-hydrox-
ylase/17,20-lyase deficiency, with a complete female phe-
notype. Patient 2 also had a mutation in the steroid-binding
domain in the second allele (D116V), but had milder com-
bined 17-hydroxylase/17,20-lyase deficiency with low, but
measurable, levels of androgens, explaining her ambiguous
genitalia. The F114V mutation (patient 1) appears to affect
steroid binding more seriously than the D116V mutation
(patient 2) both in vivo as well as in the in vitro transfection
experiments. Neither of these mutations has been described
before. Like these two mutations, all other known mutations
in the steroid-binding domain cause defects that affect 17-
hydroxylase and 17,20-lyase activities to a similar extent.
With regard to the patients with mutations in the redox
partner interaction domain, special attention should be paid
to the genotypic and phenotypic differences. Complete 17,20-
lyase deficiency results in a complete female phenotype in
46,XY individuals (patients 3 and 4), but is theoretically not
expected to result in ambiguous genitalia (patients 5 and 6).
Patients 5 and 6 are, just like one of the previously described
patients (10), homozygous for the R347H mutation and sim-
ilarly had ambiguous genitalia at birth, indicating slight re-
sidual capacity for androgen synthesis. In contrast to this,
patients 3 and 4 were heterozygous for another mutation in
the same codon (R347C), the other allele being completely
inactive due to a frameshift mutation. These two patients
(both with an 46,XY genotype) showed female genitalia at
birth and had barely detectable androgen levels. The differ-
ences between patients 5 and 6, on the one hand, and patients
3 and 4, on the other, indicate that the R347C mutation is
more deleterious for the 17-hydroxylase and/or 17,20-lyase
reaction than the R347H mutation, as is also shown by the
results of the transfection experiments. To explain the large
difference in 17-hydroxylase activity of mutations R347C
and R347H, we hypothesize that the change of arginine to
cysteine disrupts the function of the whole protein more
seriously than a change to histidine, because of the possibility
of the formation of abnormal cysteine dimers, causing not
only disruption of 17,20-lyase activity, but also of 17-
hydroxylase. In addition, the functional allele in patients 3
and 4 may be haplo-insufficient and result in residual en-
zyme activity that is too low to stimulate male genital dif-
ferentiation, whereas the homozygous presence of the R347H
mutation may cause the residual presence of sufficient 17,20-
lyase activity.
The partially virilized genitalia of patients 5 and 6 and the
ability to synthesize some testosterone in the hCG test are not
in accordance with our finding of absence of lyase activity in
vitro. As described previously, R347 and R358, which are
located in the redox partner interaction domain and contrib-
ute to the positive charges on the proximal surface of
P450c17, are known to be key residues involved in the in-
teraction with redox partner proteins. Geller et al. (20) re-
ported that the absence of these charged amino acids selec-
tively impairs 17,20-lyase activity without substantial
reductions in 17-hydroxylase activity or 17-hydroxy-
pregnenolone binding. Coexpression of the R347 and R358
mutants with P450 oxidoreductase did not result in a sig-
nificant increase in 17,20-lyase activity, but addition of excess
cytochrome b5 partially restored 17,20-lyase activity (20).
Thus, the ambiguous genitalia in R347H homozygous pa-
tients might be explained by a partial rescue of the R347H
mutation through in vivo accumulation of cytochrome b5 in
these patients.
To obtain a more detailed view of the P450c17 enzyme
function in our patients, we compared the clinical data with
in vitro expression studies. The Km values obtained for the
wild-type enzyme are in line with reported values (18, 27),
and the R347H mutation yields a lower value as described
FIG. 5. Relative production of 17-hydroxyprogesterone as a measure
of 17-hydroxylase activity () and androstenedione as a measure of
17,20-lyase activity (o) in COS-1 cells that were transiently trans-
fected with wild-type (wt) CYP17 or the CYP17 mutants and cultured
with 1M progesterone as substrate. For CYP17 wild-type transfected
cells, the 17-hydroxyprogesterone concentration was 760 nmol/liter,
and the androstenedione concentration was 33 nmol/liter. Data are
the mean  SEM (n  4).
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previously (20); these researchers also described an approx-
imately 3-fold reduction of the Vmax for this mutant enzyme.
The enzyme activities of the mutated proteins in vitro were
consistent with the clinical data and the hypothesis that
mutations in the steroid-binding domain result in combined
complete or partial 17-hydroxylase and 17,20-lyase defi-
ciency, whereas mutations in the redox partner interaction
domain result in isolated 17,20-lyase deficiency. The latter
point becomes especially clear from the results of the con-
version of pregnenolone to DHEA; although the production
of 17-hydroxypregnenolone by the cells transfected with the
R347C and R347H mutated CYP17 was larger than or com-
parable to that of the F114V and D116V cells, the amount of
DHEA produced by the former two cell types was much
lower than that secreted by the latter.
The in vitro results of the present study were obtained
using the conversion of nonradioactive precursors to prod-
ucts, which were measured by RIA. Using this type of de-
tection, Biason-Lauber et al. (13) showed that the F417C mu-
tation in P450c17 can lead to isolated 17,20-lyase deficiency;
these researchers used one dose of pregnenolone or proges-
terone as substrate. In contrast, using the conversion of tri-
tiated precursors, Gupta et al. (17) indicated that this muta-
tion affects both the 17-hydroxylase and 17,20-lyase
activities of the enzyme and argued that accurate enzymic
studies of the mutant proteins should be performed to be able
to conclude that isolated lyase deficiency is present. The
latter researchers explained the discrepancies between the
two studies on the basis of differences in the methods used
to measure the products of the enzymic conversions; RIAs
might lack the specificity needed to obtain reliable results. As
we used RIAs of nonradioactive steroids for the detection of
enzyme deficiencies of the mutated proteins, similar objec-
tions might be raised against our conclusions. However, it is
highly unlikely that insufficient specificity of our methods
plays a role, because we obtained straight lines in the
Lineweaver-Burke plots with five doses of substrate. Cross-
reacting substrates, if present, should show 100% cross-
reaction in the RIAs for 17-hydroxypregnenolone or DHEA
to explain these data. In addition, we found similar results
for the experiments using pregnenolone and progesterone
and their respective 17-hydroxylated derivatives as sub-
strates for 17-hydroxylation and lyase activities. This could
only be explained by similar problems in the assays by which
we estimated the hydroxylated C21 steroids and the C19 prod-
ucts, respectively. Moreover, the argument of Gupta et al. (17)
that substances cross-reacting in RIAs for 17-hydroxypro-
gesterone or DHEA were found in cord blood (29, 30) is not
very strong, as the substance that showed the highest cross-
reactivity in the assay for 17-hydroxyprogesterone was 17-
hydroxylated itself (29), and it would be highly unlikely to
underestimate the amount of DHEA present if other prod-
ucts would cross-react in the RIA for DHEA.
Finally, it is notable that all mutated amino acids described
in this article were well conserved during vertebrate evolu-
tion. The phenylalanine of codon 114, aspartate of codon 116,
and arginine of codon 347 are conserved in human, rat,
guinea pig, pig, medaka, trout, and frog (GenBank accession
no. NM_000102, NM_012753, S75277, Z81154, D87121,
X65800, and AF042278, respectively). This suggests that the
presence of these amino acids in these positions in P450c17
is essential for its function.
In conclusion, our clinical and in vitro expression results
confirm the differential functions of various domains in the
CYP17 gene. The P450c17 gene mutations in the steroid-
binding domain resulted in clinically combined 17-hydrox-
ylase/17,20-lyase deficiency; mutations in the redox partner
interaction domain resulted in 17,20-lyase deficiency. Re-
markably, the R347C and R347H mutations in the redox
partner domain result in different phenotypes.
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